Your browser doesn't support javascript.
The effect of the Covid-19 shutdown on glycemic testing and control.
Sharma, Anu; Greene, Dina N; Chambliss, Allison B; Farnsworth, Christopher W; French, Deborah; Herman, Daniel S; Kavsak, Peter A; Merrill, Anna E; Margaret Lo, Sheng-Ying; Lyon, Martha E; Winston-McPherson, Gabrielle; Pearson, Lauren N; SoRelle, Jeffrey A; Waring, Avantika C; Schmidt, Robert L.
  • Sharma A; Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States.
  • Greene DN; Kaiser Permanente Washington, Renton, WA, United States.
  • Chambliss AB; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
  • Farnsworth CW; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.
  • French D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
  • Herman DS; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Kavsak PA; McMaster University, Hamilton, Ontario, Canada.
  • Merrill AE; Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.
  • Margaret Lo SY; Geisinger Health, Danville, PA, United States.
  • Lyon ME; Department of Pathology and Laboratory Medicine, Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada.
  • Winston-McPherson G; Henry Ford Health System, Detroit, MI, United States.
  • Pearson LN; Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, UT.
  • SoRelle JA; University of Texas Southwestern, Dallas, TX, United States.
  • Waring AC; Kaiser Permanente Washington, Renton, WA, United States.
  • Schmidt RL; Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, UT. Electronic address: Robert.schmidt@hsc.utah.edu.
Clin Chim Acta ; 519: 148-152, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1208997
ABSTRACT

BACKGROUND:

The coronavirus disease 2019 (COVID-19) pandemic caused a halt to in-person ambulatory care. We evaluated how the reduction in access to care affected HbA1c testing and patient HbA1c levels.

METHODS:

HbA1c data from 11 institutions were extracted to compare testing volume and the percentage of abnormal results between a pre-pandemic period (January-June 2019, period 1) and a portion of the COVID-19 pandemic period (Jan-June 2020, period 2). HbA1c results greater than 6.4% were categorized as abnormal.

RESULTS:

HbA1C testing volumes decreased in March, April and May by 23, 61 and 40% relative to the corresponding months in 2019. The percentage of abnormal results increased in April, May and June (25, 23, 9%). On average, we found that the frequency of abnormal results increased by 0.31% for every 1% decrease in testing volume (p < 0.0005).

CONCLUSION:

HbA1c testing volume for outpatients decreased by up to 70% during the early months of the pandemic. The decrease in testing was associated with an increase in abnormal HbA1c results.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Experimental Studies / Observational study Limits: Humans Language: English Journal: Clin Chim Acta Year: 2021 Document Type: Article Affiliation country: J.cca.2021.04.018

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Type of study: Experimental Studies / Observational study Limits: Humans Language: English Journal: Clin Chim Acta Year: 2021 Document Type: Article Affiliation country: J.cca.2021.04.018